#0370

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer: A review of all clinical and preclinical trials.

M. Perera¹, P. Thomas²

¹Department of Urology, Princess Alexandra Hospital,, Brisbane, Australia
²Queensland Bladder Cancer Initiative (QBCI), School of Biomedical Sciences, Queensland University of Technology (QUT), Princess Alexandra Hospital, Brisbane, Australia

Introduction:

Metastatic castrate-resistant prostate cancer (mCRPC) is a rapidly fatal end-sequelae of prostate cancer. The recent development of chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the treatment of treatment-resistant haematological malignancies, and several studies are underway investigating the utility of this technology in the treatment of solid tumours. In this review, we evaluate the current treatment options for men with mCRPC as well as the current landscape of preclinical and clinical trials of CAR-T cell therapy against prostate cancer.

Material and methods:

A comprehensive literature search was conducted across multiple databases, including PubMed, EMBASE, Web of Science, and Cochrane. All clinical and pre-clinical trials were included in this narrative review. Additionally, an extensive examination of the United States National Library of Medicine clinical trials database was performed to provide a holistic overview of CAR-T trials underway.

Results:

Several tumour-associated antigens have been investigated including Prostate stem cell antigen (PSCA), Prostate specific membrane antigen (PSMA) & Epithelial Cell Adhesion Molecule (EpCAM). Preclinical trials have demonstrated promising results with marked tumour regression and even complete tumour eradication. However, this has not been recapitulated in humans to date.